Categories: Health Care

India’s highest health advisory board recommends phase out of rabbit irritation tests

Humane Society International welcomes progress towards end of cruel eye and skin tests in Indian drug sector

New Delhi, August 24, 2016: In a major milestone for Humane Society International/India’s campaign to end cruel and obsolete animal testing, the Drug Technical Advisory Board, India’s highest health advisory board, has recommended a two year phase out period for the “Draize” irritation tests using rabbits. During this transition period, validated non-animal alternatives may be accepted in place of the previously mandatory animal tests. The DTAB’s recommendation comes after a series of representations made by HSI/India, People for Animals and other stakeholders, informing the Central Drug Standard Control Organization and the Drug Controller General (India) regarding internationally recognized alternatives.

The Draize test was developed more than 70 years ago to measure eye and skin irritation using rabbits, who are locked in restraints while a test chemical is applied to one eye or to the shaved skin on their back. Animals are monitored for up to two weeks, without pain relief, for signs of chemical damage, which can include swelling, ulceration, bleeding and blindness. In addition to its obvious cruelty, the Draize test is not reliable or relevant to humans. A variety of validated and internationally recognized non-animal alternatives, including reconstructed human skin and corneal tissues, have been available for years — some since 2004. These 21st century technologies, deployed as part of a sequential testing strategy, allow complete replacement of the Draize eye and skin tests with methods that are more reproducible and reflective of human responses.

“The Drug Technical Advisory Board’s recommendation to phase out the cruel Draize test is a step in the right direction,” said Gauri Maulekhi, Government Affairs Liaison for HSI/India and PFA trustee. “However, an immediate ban would have been a more appropriate response to companies that have for years smugly disregarded the ever-growing toolbox of non-animal testing methods and their legal mandate under the Prevention of Cruelty to Animals Act, 1960 to replace animal tests when alternatives are available. We expect the Health Ministry will act swiftly to notify the rule change so that companies are required to implement it as soon as possible.”

This move comes after Union Minister of Women & Child Development, Smt. Maneka Sanjay Gandhi, wrote to the Ministry regarding the practice, followed by representations from HSI/India and PFA. India has been a full adherent to the Organization for Economic Cooperation and Development decision regarding Mutual Acceptance of Data since 2011. As a consequence, the data generated following OECD test guidelines and using Indian Good Laboratory Practice laboratories must be accepted in all the OECD member countries, and vice versa. The OECD estimates that adherence to MAD saves more than €150 million and scores of animals per year by avoiding needlessly duplicative testing.

HSI’s team of scientists and policy experts work across the globe to see outdated animal tests replaced with cutting-edge non-animal techniques.

Corporate Comm India(CCI Newswire)

 

The Pharma Times News Bureau

Recent Posts

World Diabetes Day Survey: Diabetologists and Endocrinologists demand for AI-Based Training and Upskilling in Diabetes Care

 A striking 90% of the 3000 Diabetologists and Endocrinologists surveyed, emphasised the importance of continuous…

10 hours ago

Doctors warn diabetes patients about risk of smoking

People who smoke are also at much higher risk of developing diabetes compared to non-smokers…

1 day ago

CPHI & PMEC India Expo: Encouraging affordable solutions in India’s march towards a $130 Billion Pharma Market by 2030

17th edition of CPHI& PMEC India Expo to be held from 26th November-28thNovember 2024, at the India…

1 day ago

Sringeri Sharada Equitas Hospital Revolutionizing Cancer Care with the Launch of Low-cost, High Quality Radiation Therapy

The launch signifies Equitas’ redefined commitment to bring world-class cancer radiation therapy accessible to all.…

2 days ago